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ABSTRACT 
 
Purpose: This study investigated the effects of Coleus Forskohlii (CF) on body composition, and determined 
the safety and efficacy of supplementation. Methods: In a double blind and randomized manner, 23 females 
supplemented their diet with ForsLean™ (250 mg of 10% CF extract, (n=7) or a placebo [P] (n=12) two times 
per day for 12-wks. Body composition (DEXA), body weight, and psychometric instruments were obtained at 0, 
4, 8 & 12 weeks of supplementation. Fasting blood samples and dietary records (4-d) were obtained at 0 and 12-
wks. Side effects were recorded on a weekly basis. Data were analyzed by repeated measures ANOVA and are 
presented as mean changes from baseline for the CF and placebo groups, respectively. Results: No significant 
differences were observed in caloric or macronutrient intake. CF tended to mitigate gains in body mass (-
0.7±1.8, 1.0±2.5 kg, p=0.10) and scanned mass (-0.2±1.3, 1.7±2.9 kg, p=0.08) with no significant differences in 
fat mass (-0.2±0.7, 1.1±2.3 kg, p=0.16), fat free mass (-0.1±1.3, 0.6±1.2 kg, p=0.21), or body fat (-0.2±1.0, 
0.4±1.4 %, p=0.40). Subjects in the CF group tended to report less fatigue (p=0.07), hunger (p=0.02), and 
fullness (p=0.04). No clinically significant interactions were seen in metabolic markers, blood lipids, muscle 
and liver enzymes, electrolytes, red cells, white cells, hormones (insulin, TSH, T3, and T4), heart rate, blood 
pressure, or weekly reports of side effects. Conclusion: Results suggest that CF does not appear to promote 
weight loss but may help mitigate weight gain in overweight females with apparently no clinically significant 
side effects.  Journal of the International Society of Sports Nutrition.  2(2):54-62, 2005 
 
Key Words: Weight Management, Nutritional Supplement, Lipolysis, Obesity, Herbs 
 
 
INTRODUCTION 
 
Coleus forskohlii ( C F )  i s  a  p l a n t  n a t i v e  t o  I n d i a .  
Since ancient times, plants of the Coleus species have 
been used as an herbal medicine to treat various 
disorders of the cardiovascular, respiratory, 
gastrointestinal, and central nervous systems (1). 
Forskolin has been isolated from the roots of the 
India-based  Coleus Forskohlii. One of the most 
common species that contains forskolin is Coleus 
Forskohlii  Briq.  Coleus forskohlii Briq. belongs to 
the family Labiatae, better known as the mint family. 
Chemically, it is a plant rich in alkaloids, which are 
considered to have a high probability of influence on 
the biological systems (2).   
 
Forskolin is a diterpene that acts directly on 
adenylate cyclase (3). Adenylate Cyclase is an 
enzyme that activates Cyclic Adenosine 
Monophosphate, or Cyclic AMP (cAMP) in the cell. 
Cyclic AMP promotes the breakdown of stored fats 
in animal and human fat cells (4). It regulates the 
body’s thermogenic response to food, increases the 
body’s basal metabolic rate, and increases utilization 
of body fat. It may also release fatty acids from 
adipose tissue, which results in increased 
thermogenesis, loss of body fat, and theoretically 
increased lean body mass (5). Forskolin increases 
cAMP accumulation, and therefore stimulates 
lipolysis. So, with high concentrations of forskolin, 
cAMP and lipolysis increase (4). Enhanced lipolysis 
increases fat degradation and fat usage as a fuel in the 
body (3). This may promote fat and weight loss.  It is 
thought that supplementing with forskolin may 
enhance fat loss without loss of muscle mass (6-8).   55
A previous proof-of-concept preliminary study was 
conducted to test the effects of CF on body 
composition (5).  The study used a population of six 
overweight, but otherwise healthy, women (BMI > 
25) who ingested forskolin twice daily for eight 
weeks. Each subject maintained her previous daily 
physical exercise and eating habits. The results of the 
study showed a significant decrease in the mean 
values for body weight and fat content using 
bioelectrical impedance (BIA) methodology. Lean 
body mass significantly increased compared to 
baseline. No side effects were reported.  This 
preliminary study showed that, given 25 mg of 
forskolin twice a day, overall body weight could 
improve by increasing lean body mass and by 
decreasing weight from body fat (5). 
 
A recent study conducted by Godard and colleagues 
(6) evaluated the effects of forskolin supplementation 
(250 mg of a 10% CF extract taken twice a day for 
12-weeks) in overweight and obese men (BMI > 26) 
on body composition, testosterone, metabolic rate, 
and blood pressure.  The study consisted of thirty 
participants randomized, in a double-blind, placebo-
controlled (forskolin n = 15, placebo n = 15) manner 
for 12 weeks.  Body composition determined by 
DEXA was affected due to significant decreases in 
fat percentage and fat mass when compared to the 
placebo group (p ≤ 0.05).  Bone mass changes 
occurred in the forskolin group (p ≤ 0.05) when 
compared to the placebo group.  The results of lean 
body mass revealed an increased trend when 
compared to the placebo group (p = 0.097).  In 
addition, increases in serum free testosterone 
occurred in the forskolin group compared to the 
placebo group (p ≤ 0.05).    This study showed that 
body composition decreased, bone mass increased, 
and serum free testosterone increased.  Thus, it was 
concluded that forskolin use could possibly be used 
as a therapeutic agent for weight management and 
treatment in obese men (6). 
 
The present study was needed to further investigate 
the effectiveness of CF.  Aside from its potential 
health and therapeutic benefits, additional research 
was needed to assess its role in the management of 
body composition, and to determine the safety and 
efficacy of supplementation. It was also of interest to 
the investigator how forskolin affects general 
markers of health (i.e. heart rate, blood pressure, and 
blood variables). This study took a more 
comprehensive approach to explore the role that 
forskolin supplementation has on body composition, 
fat loss, and general markers of health.  
 
 
METHODS AND MATERIALS 
 
Subjects. Nineteen (19) moderately overweight (BMI 
of 25 - 35) female subjects between the ages of 18 
and 40 participated in the study. An initial 
entry/familiarization session was held during which 
subjects completed personal and medical histories, 
and signed Informed Consent Statements. A general 
medical exam was given that included evaluating the 
medical history, performing a general physical 
examination, and evaluating whether the subjects met 
entry criteria to participate in the study. Entry criteria 
were based on age, BMI, and the presence of any 
medical condition deemed unsuitable for 
participation by the examining physician. Table 1 
presents the experimental protocol/testing schedule 
that was conducted. 
 
Table 1. Overview of Research Design 
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Pre-Supplementation / Baseline Testing.  Subjects 
recorded all food intake on dietary record forms for 
four days (4-d) prior to pre-supplementation testing.  
Subjects were instructed to refrain from exercise for 
48 hours and to fast for 8 hours prior to pre-
supplementation testing. Subjects then reported for 
the initial battery of assessments, which included an 
appetite questionnaire, a psychological mood 
inventory, and the following measurements: body 
weight, total body water, body composition, resting 
heart rate, and blood pressure.  Subjects then donated 
approximately 30 milliliters (6 teaspoons) of blood. 
 
Supplementation Protocol. After baseline testing, 
subjects were randomly and blindly assigned to 
ingest Forslean™ or a matched placebo for 12 weeks. 
The Forslean™ forskolin extract and appropriate 
placebo were prepared by Sabinsa Corporation 
(Piscataway, NJ). Capsules were provided in a 2-
piece hard shell capsule form, and delivered in 
blindly labeled bottles containing 60 capsules each.   56
Each capsule contained 250 mg of the extract 
standardized for 10% forskolin, or a suitable placebo.  
Participants were instructed to take one capsule in the 
morning and one in the evening, a half an hour before 
a meal for 12 weeks.  
 
Post-Supplementation Assessments. Subjects were 
instructed to provide weekly reports to the research 
nurse in order to monitor safety and side effects. 
Subjects who did not provide a weekly report were 
called by the research nurse to determine whether 
they had experienced any unexpected problems 
and/or adverse events.  Following 4 and 8 weeks of 
supplementation, subjects returned to have the same 
initial battery of assessments performed minus the 
blood draw and dietary history.  After 12 weeks of 
supplementation, subjects returned to repeat all 
baseline tests (including dietary history and blood 
draw).   
 
PROCEDURES 
 
Medical Monitoring. Subjects who met eligibility  
criteria were informed to report any unexpected 
problems or adverse events they encountered during 
the course of the study. The subjects were contacted 
on a weekly basis to determine if they experienced 
any unexpected problems and/or adverse events. If 
clinically significant side effects were reported, the 
subjects were to discuss the problem with the 
supervising physician to determine whether any 
medical treatment was needed and/or whether the 
subject could continue in the study. If so, the subject 
would be referred to obtain medical treatment from 
his/her personal physician.  New findings and/or 
medical referrals of unexpected problems and/or 
adverse events would be documented, placed in the 
subjects research file, and reported to the University 
of Memphis IRB committee. 
 
Dietary Inventories. Subjects recorded all food and 
fluid intake on dietary record forms.  Dietary intake 
was assessed using the Food Processor III Nutrition 
Software (Version 7.5) (Salem, OR). 
 
Appetite Scale. Appetite was assessed using a visual 
analogue scale ranging from low to high (9). This 
scale was used to record appetite, hunger, fullness, 
satisfaction, energy, and quality of food.  
 
Psychometric Inventory.  Mood changes were 
assessed by the Profile of Moods States (POMS) 
inventory (San Diego, CA) .   T h e  P O M S  i s  a  
validated, standardized self-rating scale consisting of 
57 items that measures six identifiable mood states; 
Tension-Anxiety; Depression-Dejection; Anger-
Hostility; Vigor-Activity; Fatigue-Inertia; Confusion-
Bewilderment.  A 5-point scale is used from 0 = not 
at all to 4 = extremely (10). 
 
Total Body Weight.  Prior to each assessment, height 
was measured with the shoes removed using standard 
anthropometrics. Total body weight was also 
measured with the shoes removed using a calibrated 
electronic scale with a precision of +/-0.02 kg 
(Healthometer, Bridgeview, IL). The scale was 
calibrated by placing certified 25-kg weights and 
balancing the scale. 
 
Total Body Water. Total body water was estimated 
using the Valhalla Scientific Bioelectrical Impedance 
Analyzer (Model 1990B, San Diego, CA), which 
measures bio-resistance of water and body tissues 
based on a minute low-energy, high frequency 
transmitted through the body. The analyzer was 
calibrated internally to a standard electrical current 
by pressing the calibration key located on the unit. 
After calibration was completed, subjects were 
placed in a supine position with the arms slightly bent 
at the elbows and palms facing down. The arms and 
hands were not to contact the body, and the legs were 
not allowed to touch each other. The subjects were 
instructed to remove the right shoe and sock. The 
laboratory technician sterilized the area where the 
electrodes were to be placed with a Kendall 
Webcol™ alcohol prep saturated with 70% isopropyl 
alcohol. Electrodes were placed on the posterior 
aspect of the hand and wrist, and on the anterior 
aspect of the foot and ankle.  
 
Body Composition & Bone Density.  Body 
composition was determined using a calibrated 
Hologic 4500W dual-energy x-ray absorptiometry 
(Bedford, MA) with the Hologic version V7, Rev F 
software (Waltham, MA).  The dual-energy x-ray 
absorptiometry (DEXA) segments regions of the 
body (right arm, left arm, trunk, right leg, and left 
leg) into three compartments for determination of fat, 
soft tissue (muscle), and bone mass. The scanned 
bone, fat, and fat-free/soft tissue mass for each region 
were subtotaled to determine whole body values. 
Percent body fat was calculated by dividing the 
amount of measured fat mass by total scanned mass. 
Day–to-day reliability studies of hip, spine, and 
whole body scans on men and women show the 
DEXA used in this study to be a highly reliable and 
precise method for determining variations in body 
composition segments (11). Test-retest reliability 
studies performed on male and athletes with this 
DEXA machine yielded a mean deviation for total 
BMC and total fat free/soft tissue mass of 0.31% with 
a mean intra-class correlation of 0.985 (11). Quality   57
control (QC) calibration procedures were performed 
on a spine phantom (Hologic X-CALIBER Model 
DPA/QPR-1 anthropometric spine phantom) prior to 
each testing session. In addition, weekly calibration 
procedures were performed on a density step 
calibration phantom. Testing was performed by 
certified radiology technicians who properly 
positioned the subjects in a supine manner on the 
DEXA table and executed testing according to 
standard procedures.  
 
Heart Rate & Blood Pressure.  Heart rate was 
determined by palpitation of the radial artery 
according to procedures outlined in the ACSM’s 
Guidelines for Exercise Testing and Prescription 
(12).  Blood pressure was assessed in the supine 
position after resting for 5-min with a mercurial 
sphygmomanometer (Trimline by PyMah 
Corporation, Somerville, NJ) using standard 
procedures.   
 
Blood Samples. Subjects observed an overnight eight 
(8) hour fast prior to reporting to the lab to donate 
blood. Approximately 6 teaspoons of venous blood 
(30 milliliters) were obtained through venipuncture 
of an antecubital vein in the forearm using standard 
phlebotomy procedures. Samples were collected into 
one (1) 10 mL Vacutainer SST™ gel and clot 
activator tube, and two (2) 5mL Vacutainer Brand K3 
EDTA™ sterile interior tubes. Trained laboratory 
technicians centrifuged the blood samples at 5000 rev 
x min
-1 for 10 minutes in a Biofuge 17R Centrifuge 
(Heraeus Inc., Germany). Serum from one SST tube 
was transferred into Costar microcentrifuge tubes 
(Corning Incorporated, Corning, NY) using plastic 
disposable Falcon™ transfer pipets (Becton 
Dickinson) and frozen at -80º Celsius for subsequent 
analysis. Serum from the remaining SST and EDTA 
tubes were transferred into two (2) separate 10 mL 
plain sterile tubes. The whole blood was diluted with 
2 mL of saline solution. Both serum and whole blood 
samples were refrigerated and sent to Quest 
Diagnostic Labs (Ann Arbor, MI) for clinical 
analysis.  
 
A complete 31-panel clinical chemistry profile was 
run on serum samples using the Technicon DAX 
model 96-0147 automated chemistry analyzer 
(Technicon Inc., Terry Town, NY) following standard 
clinical procedures. This panel consisted of muscle 
enzymes [creatine kinase, phosphorus, calcium]; liver 
enzymes [direct bilirubin, total bilirubin, gamma 
glutamyl transferase (GGT), lactate dehydrogenase 
(LDH), alkaline phosphatase, AST (SGOT), ALT 
(SGPT)]; lipid profile [triglycerides, total cholesterol, 
high-density lipoprotein-cholesterol (HDL-C), low-
density lipoprotein-cholesterol (LDL-C), 
cholesterol/HDLC ratio, glucose], electrolytes 
[sodium, potassium, chloride, carbon dioxide, urea 
nitrogen (BUN), creatinine, BUN/creatinine ratio], 
protein status [uric acid, total protein, albumin, 
globulin, albumin/globulin ratio], and whole blood 
cell counts [hemoglobin, hematocrit, red blood cell 
counts, white blood cell counts (basophils, absolute 
basophils, eosinophils, absolute eosinophils, 
monocytes, absolute monocytes, lymphocytes, 
absolute lymphocytes, neutrophils, absolute 
neutrophils), platelet count, mean corpuscular volume 
(MCV), mean corpuscular hemoglobin (MCH), mean 
corpuscular hemoglobin concentration (MCHC), red 
cell distribution width (RDW)]. Cell counts with 
percent differentials were run on whole blood 
samples using a Coulter STKS automated analyzer 
(Coulter Inc., Hialeah, FL) using standard 
procedures.   
 
Frozen serum samples were sent to the Department of 
Physiology at East Tennessee State University to 
assay thyroid stimulating hormone (thyrotropin), 
thyroxin, total thyroxin, and fasting insulin. A 
chemistry profile was run on these samples using an 
Immulite Mark 5 HSS chemiluminescence random 
access immunoassay analyzer (Diagnostic Products 
Corporation, Los Angeles, CA) following standard 
procedures. These analyzers were calibrated daily to 
controls according to manufacturer recommendations 
and federal guidelines for clinical diagnostic 
laboratories. Test to test reliability of performing 
these assays ranged from 2 to 6% for individual 
assays with a average variation of ±3%. Samples 
were run in duplicate to verify results if the observed 
values were outside control values and/or clinical 
norms according to standard procedures (13). 
Analysis of these blood parameters helped determine 
the safety effects of this nutritional supplementation 
formulation on general markers of clinical health 
status and selected hormones.   
 
DATA ANALYSIS 
 
A 2 (groups) x 4 (times) analysis of variance 
(ANOVA) test with repeated measures on the second 
factor was performed on five variables: total body 
weight, total body water, body composition, appetite 
surveys, and psychological mood state inventories. A 
2 X 2 ANOVA test with repeated measures on the 
second factor was performed on the diet logs and the 
clinical profiles for the blood samples. Type I error 
was controlled at 0.05 for all of the data analysis  
   58
Table 2.  Four-day total dietary intake for the CF and P groups.   
Variable Group  Week 0 
(T1) 
Week 8 
(T3) 
Week 12 
(T4)  Significance 
Fat 
(g/kg/d) 
CF 
P 
281.5±87.5 
337.0±124.2 
243.2±69.0 
310.1±99.1 
187.0±55.8 
219.0±86.3 
Group 
Time 
Group x Time 
0.153 
0.002 
0.696 
Carbohydrates 
(g/kg/d) 
CF 
P 
959.1±278.7 
959.7±253.6 
903.5±227.9 
953.3±269.2 
777.5±303.2 
831.5±184.1 
Group 
Time 
Group x Time 
0.719 
0.025 
0.676 
Protein 
(g/kg/d) 
CF 
P 
293.8±112.0 
318.5±143.5 
270.8±93.0 
290.7±129.9 
242.8±80.7 
282.1±77.6 
Group 
Time 
Group x Time 
0.525 
0.213 
0.831 
Energy Intake 
(kcal/kg/d) 
CF 
P 
7458±1920 
8087±2310 
6833±1259 
7772±2165 
5690±1927 
6435±1475 
Group 
Time 
Group x Time 
0.299 
0.007 
0.919 
 
 
Table 3.  Selected hematological markers for the CF and P groups.   
Variable Group  Week 0 
(T1) 
Week 12 
(T4)  Significance 
White Blood  
Cells 
(thous/cum) 
CF 
P 
6.5±1.8 
5.9±1.7 
7.9±2.3 
5.1±1.7 
Group 
Time 
Group x Time 
0.030 
0.366 
0.007 
Absolute 
Lymphocytes 
(cells/mcl) 
CF 
P 
2161.2±433.6 
2084.4±511.4 
2771.0±643.2 
1945.8±447.5 
Group 
Time 
Group x Time 
0.051 
0.043 
0.003 
Calcium 
(mg/dl) 
CF 
P 
9.1±0.1 
9.3±0.2 
9.3±0.4 
9.1±0.2 
Group 
Time 
Group x Time 
0.894 
0.904 
0.030 
ALT (SGPT) 
(U/L) 
CF 
P 
11.8±4.6 
22.5±10.1 
11.4±3.4 
22.0±13.8 
Group 
Time 
Group x Time 
0.020 
0.036 
0.000 
Uric Acid 
(mg/dl) 
CF 
P 
4.2±0.9 
3.9±1.1 
3.8±1.0 
4.4±1.4 
Group 
Time 
Group x Time 
0.006 
0.724 
0.003 
Absolute 
Neutrophils 
(cells/mcl) 
CF 
P 
3791.9 ±1273.0 
3270.7±1251.3 
4467.7±1737.2 
2732.5±596.0 
Group 
Time 
Group x Time 
0.042 
0.787 
0.027 
 
 
procedures. Tukey least significant difference (LSD) 
post-hoc procedures were conducted when a 
significance level was observed. Delta values were 
calculated on body composition variables to further 
highlight significant changes that occurred during the 
study. 
 
RESULTS 
 
Nutritional Intake. Table 2 presents four day total 
nutritional intake data for the CF and P groups.  No 
significant group interactions (p>0.05)  were 
observed in mean relative daily energy intake,  
carbohydrate intake, protein intake, or fat intake. 
However, daily intake for the energy, carbohydrate,  
 
and fat variables significantly decreased (p < 0.05) 
from Week 0 to Week 12. 
 
Medical Safety Analysis. Table 3 presents significant 
blood markers obtained throughout the study.  These 
hematological responses were measured for the 
analysis of the safety of the supplement on general 
markers of health. The results of the analysis 
indicated a significant group interaction in white 
blood cell levels (p=0.007), absolute lymphocyte 
levels (p=0.003), absolute neutrophils (p = 0.027), 
calcium levels (p=0.03), ALT (p=0.000), and uric 
acid (p=0.003) for the CF group. Additionally, a 
significant group effect (p < 0.05) was observed in 
red blood cell count, % hematocrit, MCV, MCH,    59
Table 4. Body composition and bone density values for the CF and P groups 
Variable Group  Week 0 
(T1) 
Week 4 
(T2) 
Week 8 
(T3) 
Week 12 
(T4)  Significance 
Body 
Weight 
(kg)  
CF 
P 
87.2±12.4 
86.1±12.5 
86.8±12.1 
86.1±15.3 
86.5±12.8 
87.1±14.3 
86.6±13.0 
87.4±13.4 
Group 
Time 
Group x Time 
0.987 
0.492 
0.121 
Bone 
Mineral 
Area 
(cm
2) 
CF 
P 
1772±94 
1846±116 
1772±121 
1861±110 
1755±127 
1855±106 
1781±130 
1844±120 
Group 
Time 
Group x Time 
0.148 
0.929 
0.756 
Bone 
Mineral 
Content 
(g) 
CF 
P 
1781±202 
1872±237 
1788±206 
1874±223 
1759±226 
1874±232 
1803±223 
1870±242 
Group 
Time 
Group x Time 
0.412 
0.663 
0.601 
Bone 
Mineral 
Density  
(g/cm
2 ) 
CF 
P 
1.0±0.08 
1.0±0.08 
1.0±0.07 
1.0±0.07 
0.9±0.07 
1.0±0.08 
1.0±0.07 
1.0±0.08 
Group 
Time 
Group x Time 
0.923 
0.367 
0.578 
Fat Mass  
(kg) 
CF 
P 
33.82±8.00 
31.27±7.22 
33.77±8.38 
31.69±7.94 
33.66±8.17 
32.20±8.70 
33.61±8.37 
32.36±8.22 
Group 
Time 
Group x Time 
0.638 
0.336 
0.161 
Lean Mass 
(kg) 
CF 
P 
44.65±5.75 
46.40±6.18 
44.40±4.88 
46.47±6.45 
44.69±5.44 
47.01±5.97 
44.59±5.53 
47.05±5.62 
Group 
Time 
Group x Time 
0.446 
0.168 
0.212 
Lean + 
BMC 
(kg) 
CF 
P 
46.43±5.88 
48.27±6.36 
46.18±5.01 
48.35±6.63 
46.45±5.57 
48.88±6.16 
46.40±5.66 
48.92±5.81 
Group 
Time 
Group x Time 
0.440 
0.154 
0.211 
Total Mass 
(kg) 
CF 
P 
80.25±12.42 
79.54±12.70 
79.96±11.93 
80.04±13.60 
80.11±12.59 
81.08±13.81 
80.017±12.7 
81.28±13.01 
Group 
Time 
Group x Time 
0.948 
0.139 
0.080 
Body Fat  
(%) 
CF 
P 
41.8±4.7 
39.0±3.7 
41.8±5.0 
39.5±4.0 
41.6±4.4 
39.2±4.6 
41.6±4.8 
39.3±4.3 
Group 
Time 
Group x Time 
0.243 
0.923 
0.395 
Body 
Water 
(%) 
CF 
P 
43.9±4.0 
46.1±3.2 
44.1±3.6 
46.1±3.6 
45.5±3.8 
46.1±3.2 
45.3±4.3 
47.3±5.2 
Group 
Time 
Group x Time 
0.289 
0.200 
0.802 
 
 
total bilirubin, glucose, BUN/creatinine ratio, and 
cholesterol/HDL ratio within the P and CF groups. A 
significant decrease was noted in all of the values 
except for total bilirubin, which significantly 
increased within both groups. The cholesterol/HDL 
ratio also significantly increased within the P group.  
 
There was a significant time effect (p < 0.05) in 
hemoglobin levels, glucose, albumin levels, red cell 
dimension width, and creatine kinase from Week 0 to 
Week 12. No significant group interactions (p>0.05) 
were observed in the blood lipid profile, 
hemodynamic, hormone, insulin variables, or weekly 
reports of side effects.  All values remained within 
normal clinical parameters.  
 
Body Composition. Table 4 presents body 
composition data obtained during each of the four 
testing trials, and Figure 1 presents mean changes in  
 
body composition data from Week 0 to Week 12. 
There were no significant differences (p>0.05) in 
body weight , bone mineral area, bone mineral 
density, fat mass, lean mass, % body fat, or % body 
water observed between the two groups. In addition, 
there was no significant interaction (p>0.05) amongst 
the groups in body composition. Group trends 
occurred in total mass (p=0.08). 
 
Psychological Profiles. A significant time effect was 
noted for tension/anxiety (p = 0.006) in the 
psychological analysis of mood. Group trends 
occurred in fatigue (p = 0.07) between P and CF 
from Week 0 to Week 12. No other significant 
differences were observed. 
 
Appetite Profiles. Table 5 presents the appetite data 
obtained during each of the four testing trials. There 
were no significant changes observed in appetite,    60
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Figure 1. The upper left panel depicts changes in DEXA total scanned mass (g), the upper right panel illustrates changes in DEXA fat-
free mass (g), the lower left panel highlights differences in DEXA lean mass (g), and the lower right panel shows changes in DEXA % 
body fat from Week 0 to Week 12 for CF (♦) and P (■). 
 
 
amount of energy, or overall quality of food. The 
analysis indicated a significant time effect (p = 
0.026) in satisfaction from food in both groups from 
Week 0 to Week 12. There was a significant decrease 
observed in the feelings of fullness variable (p = 
0.04) for group CF from Week 0 to Week 12.  
 
DISCUSSION 
 
The major findings of this study were: 1.) 12-weeks 
of CF supplementation (250 mg of a 10% CF extract 
taken two times per day) did not promote weight loss 
but may have helped mitigate weight gain in free-
living overweight females; and, 2.) CF 
supplementation did not adversely affect markers of 
health status.  However, some interesting findings 
were observed that warrant additional research.  The  
following discusses the results of this study in greater 
detail.  
 
Dietary Intake. The subjects involved in the study 
recorded all food and fluid intake during Week 0 and 
Week 12 of the testing sessions. Significant decreases 
were seen in carbohydrate, fat, and energy intake for 
both groups over time. No significant differences 
were observed between CF and P, which suggest that 
supplementation had no significant effect on diet.  
 
The changes over time could reflect subject efforts to 
decrease food intake in an attempt to assist in the 
weight loss process. It is possible that more group 
differences could have been observed if a specific 
diet were implemented into the study. This would 
allow for the effects of supplementation to be more 
closely monitored.  
 
Medical Safety Analysis. One purpose of this study 
was to determine the safety effects of forskolin 
supplementation on general markers of health. This 
was measured by monitoring changes in heart rate 
and blood pressure taken during each testing session, 
and serum and whole blood samples collected during 
Week 0 and Week 12 of the study.   Previous 
research indicated that CF causes an increase in heart 
rate and a decrease in blood pressure (14-15). 
However, the results of this analysis showed that 
supplementation had no significant effect on either 
variable. The blood samples collected were assayed 
for muscle and liver enzymes, lipid profile, 
electrolytes, protein status, thyroid hormones, fasting 
insulin, and whole blood cell counts. Significant 
changes were observed from Week 0 to Week 12 in 
Group CF in white blood cell count, absolute 
lymphocyte count, absolute neutrophil count, calcium 
levels, ALT, and uric acid levels. Supplementation  
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Table 5.  Appetite markers for the CF and P groups. 
Variable Group  Week 0 
(T1) 
Week 4 
(T2) 
Week 8 
(T3) 
Week 12 
(T4)  Significance 
Appetite  CF 
P 
4.8±0.3 
5.1±0.8 
4.7±1.4 
4.1±1.6 
4.4±1.1 
4.3±1.4 
4.5±0.7 
5.1±1.1 
Group 
Time 
Group x Time 
0.829 
0.673 
0.581 
Hunger  CF 
P 
4.0±1.2 
4.9±1.1 
3.8±1.0 
4.0±1.5 
4.0±1.8 
4.1±1.1 
3.1±1.5 
5.2±1.0 
Group 
Time 
Group x Time 
0.054 
0.645 
0.165 
Satisfaction 
from Food 
CF 
P 
5.8±1.7 
6.1±1.4 
5.0±0.5 
5.9±1.3 
4.4±1.2 
5.5±1.9 
4.7±1.9 
5.8±1.1 
Group 
Time 
Group x Time 
0.138 
0.026 
0.242 
Feeling of 
Fullness 
CF 
P 
5.8±1.3 
6.3±1.3 
4.7±0.9 
5.9±1.7 
5.0±2.1 
6.1±1.8 
4.1±1.3 
6.4±1.5 
Group 
Time 
Group x Time 
0.040 
0.086 
0.042 
Amount of 
Energy 
CF 
P 
5.9±2.0 
5.8±1.2 
5.2±1.3 
6.0±1.2 
5.5±2.5 
5.9±1.4 
5.5±1.9 
5.8±1.7 
Group 
Time 
Group x Time 
0.611 
0.781 
0.785 
Overall 
Quality of 
Food 
CF 
P 
4.8±1.5 
5.2±1.4 
5.1±1.8 
5.7±1.0 
4.5±1.1 
5.6±1.3 
4.0±1.7 
5.6±1.4 
Group 
Time 
Group x Time 
0.102 
0.472 
0.134 
 
 
resulted in an increase in calcium, white blood cell, 
absolute lymphocyte, and absolute neutrophil counts. 
Decreases were observed in ALT and uric acid levels. 
These variables contribute to muscle, immune, liver, 
and protein functions, respectively, in the body. Even 
though these changes occurred, the values remained 
within normal ranges and were relatively small.   
Additionally, no significant adverse events were 
reported during the study that could be attributed to 
the supplementation protocol.  Therefore, these 
findings suggest that CF supplementation does not 
appear to be associated with any significant clinical 
side effects. 
 
Body Composition. This study was also conducted 
with the purpose of investigating the effectiveness of 
CF on the management of body composition.  Body 
composition was analyzed by examining measures of 
body weight, body water, and bone density. Previous 
research suggests that forskolin is associated with 
increased lipolysis, which would increase fat and 
weight loss in the body (13). The findings from the 
previous pilot study suggested that supplementation 
significantly decreases body weight and fat, and 
significantly increases lean body mass in free living 
subjects (5).  The results from this study did not 
replicate those findings.  Additionally, results 
contrast recent findings by Godard and colleagues (6) 
who reported that 12-weeks of CF (250 mg of a 10% 
CF preparation taken two times per day) promoted 
favorable changes in body composition in overweight 
men.   In the present study, no significant changes  
 
were observed in body weight, fat content, or lean 
body mass.  However, statistical trends were found in 
total scanned mass, which could suggest some 
alleviation in weight gain among overweight 
subjects.  Overall, CF had no effect on the fat free or 
fat mass of the female subjects used in the study.  It is 
possible that more group differences could be seen if 
controls for exercise and/or diet were incorporated 
and/or the study was conducted in a larger 
population.  
 
Psychological Analysis. A psychometric inventory 
was used to analyze mood changes during each of the 
four testing sessions of the study. This analysis 
measured potential changes in six different mood 
states: tension-anxiety, depression-dejection, anger-
hostility, vigor-activity, fatigue-inertia, and 
confusion-bewilderment. The results of this 
psychological inventory revealed that regular 
ingestion of the supplement produced no significant 
alteration in mood, except for the decrease in tension-
anxiety over time. This decrease could be associated 
with the possible effects of supplementation on body 
weight, which is an issue that often leads to tension-
anxiety. Trends were observed in fatigue levels. 
Subjects taking the supplement appeared to 
experience less fatigue over the course of the study. 
Because there were no controls for physical activity 
in this study, only speculation can explain the 
changes that occurred. It is possible that those in CF 
engaged in less activity with the idea that 
supplementation would increase weight loss.    62
Appetite Analysis. An appetite inventory was used to 
assess variables of appetite during each of the four 
testing sessions of the study. This inventory 
measured changes in hunger, appetite, satisfaction 
from food, fullness, and overall quality of food. No 
significant differences were observed in appetite, 
hunger, energy, or overall quality of food. This shows 
that the eating desires for both groups were 
maintained. However, the significant time effect in 
satisfaction from food found in CF and P suggests 
that both groups received less enjoyment from the 
food consumed. There was also a significant decrease 
noted in feelings of fullness in CF from Week 0 to 
Week 12. Even though appetite and hunger were not 
significantly affected by supplementation, it is 
possible that because CF received less satisfaction 
from food that less food was eaten.  
 
Summary. In conclusion, this study was performed in 
an attempt to further investigate the effectiveness of 
CF on body composition and general markers of 
health. The findings suggest that 12-weeks of CF 
supplementation in free-living subjects have limited 
effects on body composition and no apparent 
clinically significant side effects.  However, CF has 
the potential to positively influence the loss and 
management of overall body weight possibly as a 
means of maintaining weight after weight loss.  Still, 
future research is needed to further explore its 
capabilities.  
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